Sunesis Pharmaceuticals (FRA:RYIS) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sunesis Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2020 was 0.00.

Sunesis Pharmaceuticals's long-term debt to total assets ratio declined from Dec. 2019 (0.01) to Dec. 2020 (0.00). It may suggest that Sunesis Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Sunesis Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Sunesis Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals LT-Debt-to-Total-Asset Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.26

0.01

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	-	-	-	-

Sunesis Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Sunesis Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as

LT Debt to Total Assets (A: Dec. 2020 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2020 )	/	Total Assets (A: Dec. 2020 )
	=	0	/	19.109
	=	0.00

Sunesis Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2020 is calculated as

LT Debt to Total Assets (Q: Dec. 2020 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2020 )	/	Total Assets (Q: Dec. 2020 )
	=	0	/	19.109
	=

Sunesis Pharmaceuticals (FRA:RYIS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sunesis Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines